Sight Sciences, Inc. (SGHT)

Market Cap	181.19M
Revenue (ttm)	76.30M
Net Income (ttm)	-49.01M
Shares Out	52.37M
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,054
Open	3.540
Previous Close	3.620
Day's Range	3.500 - 3.580
52-Week Range	2.030 - 7.030
Beta	2.46
Analysts	Buy
Price Target	4.29 (+21.88%)
Earnings Date	Nov 6, 2025

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 216
• Stock Exchange: NASDAQ
• Ticker Symbol: SGHT
• Website: https://www.sightsciences.com

Financial Performance

In 2024, Sight Sciences's revenue was $79.87 million, a decrease of -1.47% compared to the previous year's $81.06 million. Losses were -$51.51 million, -7.27% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price target is $4.29, which is an increase of 21.88% from the latest price.

Price Target

$4.29

(21.88% upside)

Analyst Consensus: Buy